Headed by:
Mr.
S.Rajasekar
Manager (R&D).
Arvind Research Centre (ARC) boasts of a sophisticated
Research & Development Laboratory well-equipped
with the latest Technologies and Machineries.
Our well-qualified and committed R&D Team of
over 15 Research Scientists, Doctors, Ayurvedic
Specialists and Chemists are the primary driving
force in our R&D efforts.
Our focus areas
are Development of Drug Delivery Systems, New
Formulations, Process Development of Various Dosage
Forms. The six major areas where R&D works
on are:
1. Ayurvedic
Formulation Development
2. Allopathic
Formulation Development
3. Process Development
and Validation
4. Novel drugs
delivery development
5. Nutraceuticals
6. Analytical
Development.
Today, the Indian Pharmaceutical industry is on
the verge of undergoing a paradigm shift. While
preparing to meet the challenges of product patent
regime, it is reformulating its growth strategies
to make its mark in the global arena. The foundations
of this are based in solid research, which is
the crux of any technological innovation.
Our high-tech
research center has been set up at Kakkalur, Tamil
Nadu for the enhancement of Our research capabilities
with focus on the core areas of Diabetology, Cardiology
and Nephrology using age-old Herbal Medicines,
Nutraceuticals and anti infective segments.
Key Focus Areas
and Products
In the Diabetology segment, PANKARE a herbal
combination is found as an efficient treatment
for Diabetes developed by our R&D. PANKARE
Tablets is a scientifically and clinically developed
herbal formulation for treatment of Diabetes and
offers restoration, regeneration and rejuvenation
of pancreatic beta cells. It also possesses anti-oxidant,
anti-hypertensive and hypocholesterolmic properties.
In the Cardiology segment, ARC 1056, a
Herbal combination was developed to treat Coronary
Artery Disease and cure Cardio Vascular Problems,
ARC 1056 has entered Phase II clinical trials
after successful completion of Phase I clinical
studies with the increase in the incidents of
Cardio Vascular problems, owing to stressful modern
day lifestyle, this segment holds great potential
for development.
In the Nephrology segment, ARC 2098,
a herbal combination indicated for patients undergoing
dialysis has entered Phase I of clinical trial.
In the Dermatology
segment, Sorexil brings solace to the
un-addressed problem of Bedsores in chronic bedridden
patients. It is an indigenous combination of Aloe,
Neem Oil, Castor Oil with PMFA Technology and
offers relief from Bedsores, Diabetic Ulcers,
Pressure Sores, Venous Ulcers, Burns, Cuts and
Wounds. Besides healing wounds, Sorexil leaves
lesser marks and no Keloids. We are perhaps the
first Company to introduce a cure for Bed sores,
through this Ayurvedic product in the form of
trans dermal delivery.
Another herbal combination indicated
for wound dressings, ARC 190, is in the
Phase II clinical trials. This product is an extension
of Sorexil. ARC 190 dressings with Sorexil gel
is a revolution in this area. So far the Clinical
trials have shown excellent results. Surgical
wound dressing has a huge market potential of
over Rs.300 Crores and the need is enormous. This
product is a boon to Surgeons and to suffering
patients.
We have two unique products of
solufact'O' & solufact'C' which are proven
for its efficiency in reducing weight promisingly
in obese people and help in controlling blood
chloesterols. Both are clinically proven in Phase
II.
In Nutraceuticals, we are developing
products for Pregnant Women, Diabetics, Geriatrics
and Cardiac patients.
Our R & D pipeline has a number of Herbal products,
in the development stage, and a new Herbal Product
is expected to be launched every 9 to 12 months.
Pharmaceutical Research is an ongoing
process and it is what adds value to the Company's
presence in Domestic and International markets.
We have a constant thrust on the creation of Intellectual
Property for higher value addition.
Our scope of R&D is to standarise
the system of process right from zero start to
market end where our international compliance
is always above its required specification as
an example for others.